Alliancebernstein L.P. Omeros Corp Transaction History

Alliancebernstein L.P.

$300 Billion
Q3 2025

A detailed history of Alliancebernstein L.P. transactions in Omeros Corp stock. As of the latest transaction made, Alliancebernstein L.P. holds 67,590 shares of OMER stock, worth $500,841. This represents 0.0% of its overall portfolio holdings.

Number of Shares

67,590

Previous 67,590 -0.0%

Holding current value

$500,841

Previous $202,000 37.13%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$3.0 - $8.01 $49,800 - $132,966	16,600 Added 32.56%	67,590 $202,000
Q4 2024 Feb 12, 2025	BUY	$3.77 - $12.15 $116,379 - $375,070	30,870 Added 153.43%	50,990 $503,000
Q2 2024 Aug 14, 2024	BUY	$3.04 - $4.23 $25,596 - $35,616	8,420 Added 71.97%	20,120 $81,000
Q2 2023 Aug 15, 2023	BUY	$4.45 - $7.57 $52,065 - $88,569	11,700 New	11,700 $63,000
Q2 2022 Aug 15, 2022	SELL	$1.92 - $6.28 $134,400 - $439,600	-70,000 Closed	0 $0

Q1 2022 May 13, 2022	BUY	$5.07 - $7.2 $507 - $720	100 Added 0.14%	70,000 $421,000
Q3 2020 Nov 12, 2020	SELL	$9.57 - $21.32 $16,269 - $36,244	-1,700 Reduced 2.37%	69,900 $706,000
Q2 2020 Aug 13, 2020	SELL	$12.21 - $16.99 $15,873 - $22,086	-1,300 Reduced 1.78%	71,600 $1.05 Million
Q1 2020 May 14, 2020	BUY	$9.03 - $19.72 $25,284 - $55,216	2,800 Added 3.99%	72,900 $975,000
Q3 2018 Nov 08, 2018	BUY	$17.73 - $26.69 $30,141 - $45,373	1,700 Added 2.49%	70,100 $1.71 Million
Q1 2018 May 14, 2018	BUY	$9.0 - $20.16 $83,700 - $187,488	9,300 Added 15.74%	68,400 $764,000
Q4 2017 Feb 13, 2018	SELL	$13.26 - $22.86 $31,824 - $54,864	-2,400 Reduced 3.9%	59,100 $1.15 Million
Q3 2017 Nov 13, 2017	BUY	$19.76 - $24.9 $1.22 Million - $1.53 Million	61,500	61,500 $1.33 Million

Others Institutions Holding OMER

# of Institutions

154

Shares Held

33.1M

Call Options Held

2.2M

Put Options Held

2.72M

View Full List

About OMEROS CORP

Ticker OMER
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,730,000
Market Cap $465M
Description
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical program...

More about OMER

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Omeros Corp Transaction History